Details of Drug Interaction

Details of Drug-Drug Interaction

 Drug General Information (ID: DDIBKI5QZA)
  Drug Name Amphotericin B (cholesteryl sulfate) Drug Info Rabeprazole Drug Info
  Drug Type Small molecule Small molecule
  Therapeutic Class Antifungal Agents Antiulcer Agents
  Structure

 Mechanism of Amphotericin B (cholesteryl sulfate)-Rabeprazole Interaction (Severity Level: Moderate)
     Increased risk of hypomagnesemia Click to Show/Hide Mechanism Graph
Could Not Find 2D Structure
      Drug Name Amphotericin B (cholesteryl sulfate) Rabeprazole
      Mechanism Hypomagnesemia Hypomagnesemia
      Key Mechanism Factor 1
Factor Name Hypomagnesemia
Factor Description Hypomagnesemia is a condition that occurs when you have too much magnesium in your body. Symptoms of hypomagnesemia include: nausea, vomiting, neurological damage, abnormally low blood pressure (hypotension), flushing, and headaches.
      Mechanism Description
  • Increased risk of hypomagnesemia by the combination of Amphotericin B (cholesteryl sulfate) and Rabeprazole 

Recommended Action
      Management Monitoring of serum magnesium levels is recommended prior to initiation of therapy and periodically thereafter if prolonged treatment with a proton pump inhibitor is anticipated or when combined with other agents that can cause hypomagnesemia such as diuretics, aminoglycosides, cation exchange resins, amphotericin B, cetuximab, cisplatin, cyclosporine, foscarnet, panitumumab, pentamidine, and tacrolimus. Patients should be advised to seek immediate medical attention if they develop potential signs and symptoms of hypomagnesemia such as palpitations, arrhythmia, muscle spasm, tremor, or convulsions. In children, abnormal heart rates may cause fatigue, upset stomach, dizziness, and lightheadedness. Magnesium replacement as well as discontinuation of the PPI may be required in some patients.

References
1 Product Information. Nexium (esomeprazole) Astra-Zeneca Pharmaceuticals, Wilmington, DE.
2 Wohlt PD, Zheng L, Gunderson S, Balzar SA, Johnson BD, Fish JT "Recommendations for the use of medications with continuous enteral nutrition." Am J Health Syst Pharm 66 (2009): 1438-67. [PMID: 19667002]
3 FDA. U.S. Food and Drug Administration "FDA Drug Safety Communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs).".